雌激素受体检测对大型乳腺癌的不同预测价值。
The differing predictive values of oestrogen receptor assays for large breast cancers.
作者信息
Gaskell D J, Hawkins R A, Tesdale A L, Sangster K, Chetty U, Forrest A P
机构信息
University Department of Surgery, Royal Infirmary, Edinburgh, UK.
出版信息
Postgrad Med J. 1992 Nov;68(805):900-3. doi: 10.1136/pgmj.68.805.900.
Thirty elderly patients with T3 or T4 breast cancer underwent a wedge biopsy for radioligand-binding assay (RLA) of oestrogen receptor (ER) activity. A second, separate group of 21 elderly patients with T3 and T4 breast cancers underwent fine needle aspiration biopsy (FNA) for immunocytochemical assay of ER (ER-ICA). All the women received tamoxifen as primary treatment and response was assessed by UICC criteria. Tumour ER concentration by RLA was correlated with both response (Spearman's R = + 0.52) and time to progression (R = + 0.76). Nine patients with receptor-rich tumours (> 100 fmol/mg protein) failed to show a response. However, the percentage of cells staining for ER by ER-ICA assay was much more strongly related to the likelihood of response (R = + 0.89); no patient with < 20% cells staining responded. Wedge biopsy and the biochemical determination of ER activity is of limited value in predicting the likely response to tamoxifen; ER-ICA assays on such tumours may be more informative.
30例T3或T4期乳腺癌老年患者接受楔形活检，用于雌激素受体（ER）活性的放射性配体结合分析（RLA）。另一组21例T3和T4期乳腺癌老年患者接受细针穿刺活检（FNA），用于ER的免疫细胞化学分析（ER-ICA）。所有女性均接受他莫昔芬作为初始治疗，并根据国际抗癌联盟（UICC）标准评估疗效。通过RLA检测的肿瘤ER浓度与疗效（Spearman相关系数R = +0.52）和进展时间（R = +0.76）均相关。9例ER丰富肿瘤（>100 fmol/mg蛋白）患者未显示出疗效。然而，通过ER-ICA分析检测到的ER染色细胞百分比与疗效可能性的相关性更强（R = +0.89）；染色细胞<20%的患者均无疗效。楔形活检及ER活性的生化测定在预测他莫昔芬可能的疗效方面价值有限；对此类肿瘤进行ER-ICA分析可能更具信息价值。
Zotero 插件